Psoriasis improvement in patients using glutathione-enhancing, nondenatured whey protein isolate: A pilot study

Journal of Clinical and Aesthetic Dermatology

Volumn 6, Issue 10, 2013, Pages 23-26

  Prussick, Ronald ^a,b   Prussick, Lisa ^a   Gutman, Jimmy ^c,d  

^a Dermatology Center   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d Immunotec Research   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; GLUTATHIONE; IMMUNOCAL; UNCLASSIFIED DRUG; WHEY PROTEIN;

ABSENCE OF SIDE EFFECTS; ARTICLE; HUMAN; NARROW BAND IMAGING; PHOTOGRAPHY; PROSPECTIVE STUDY; PROTEIN ISOLATION; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; TOPICAL TREATMENT; ULTRAVIOLET B RADIATION; WHEY;

EID: 84886732770     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Prussick R, Prussick L. Biologic therapies for psoriasis in 2013: do we use them enough? Practical Dermatol. 2013;10(2):32-34.
2. Wozniak A, Drewa G, Krzyzynska-Maliniowska E, et al. Oxidant-antioxidant balance in patients with psoriasis. Med Sci Monit. 2007;13(1):CR30-CR33.
3. Yildirim M, Inaloz HS, Baysal V, Delibas N. The role of oxidants and antioxidants in psoriasis. J Eur Acad Dermatol Venereol. 2003;17:34-36.
4. Aceto A, Martini F, Dragani B, et al. Purification and characterization of glutathione transferase from psoriatic skin. Biochem Med Metab Biol. 1992;48:212-218.
5. Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. Erythrocyte damage in mild and severe psoriasis. Br J Dermatol. 2004;150(2):232-244.
6. Kaur S, Zilmer K, Kairane C, et al. Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. Br J Dermatol. 2008;159(6):1364-1367.
7. Flagg EW, Coates RJ, Eley JW, et al. Dietary glutathione intake in humans and the relationship between intake and plasma total glutathione level. Nutr Cancer. 1994;21(1):33-46.
8. Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of oral glutathione. Eur J Clin Pharmacol. 1992;43(6):667-669.
9. Lands LC, Grey VL, Smountas AA. The effect of supplementation with a cysteine donor on muscular performance. J Appl Physiol. 1999;87(4):1381-1385
10. Hodgman MJ, Garrard AR. A review of acetaminophen poisoning. Crit Care Clin. 2012;28(4):499-516.
11. Ellis JH, Cohan RH. Prevention of contrast-induced nephropathy: an overview. Radiol Clin North Am. 2009;47(5):801-811.
12. Sandilands EA, Bateman DN. Adverse effects associated with acetylcysteine. Clin Toxicol. 2009;47(2):81-88.
13. PDR (Physician's Desk Reference) Vol. 67, 2013, p. 2762-2763. PDR Network LLC. Montvale N.J. USA.
14. CPS (Compendium of Pharmaceuticals & Specialties) 2013, p. 1510.
15. CANADIAN ASSOCIATION OF PHAMACISTS, Ottawa, ON, Canada
16. Bounous G. Whey protein concentrate and glutathione modulation in cancer treatment. Anticancer Res. 2000;20(6C):4785-4792.
17. Baruchel S, Viau G, Olivier R, et al. Nutriceutical modulation of glutathione with a humanized native milk serum protein isolate, Immunocal: application in AIDS and cancer. In: Luc Montagnier et al. Oxidative Stress in Cancer, AIDS and Neurodegenerative Diseases, 1st ed. New York, NY: Marcel Dekker Inc; 1998: 447-461.
18. Kennedy RS, Konok GP, Bounous G, et al. The use of a whey protein concentrate in the treatment of patients with metastatic carcinoma: a Phase I-II clinical study. Anticancer Res. 1995;15:2643-2650.
19. Bounous G, Baruchel J, Gold P. Whey proteins as a food supplement in HIV-seropositive individuals. Clin Invest Med. 1993;16:204-209.
20. Grey V, Mohammed SR, Smountas AA, et al. Improved glutathione status in young adult patients with cystic fibrosis supplemented with whey protein. J Cyst Fibros. 2003;2:195-198.
21. Tozer R, Tai P, Falconer W, et al. Cysteine-rich protein reverses weight loss in lung cancer patients receiving chemotherapy or radiotherapy. Antiox & Redox Signaling. 2008;10:395-402.
22. Kern JK, Grannemann BD, Gutman J, Trivedi MH. Oral tolerability of cysteine-rich whey protein isolate in autism - a pilot study. JANA. 2008;11:36-41.
23. Seifert O, Holmberg J, Linnarsson BM. Decreased activity of neutrophil glutathione peroxidase in chronic plaque-type psoriasis. J Am Acad Dermatol. 2007;57(3):528-529.
24. Drewa G, Krzyzyńska-Malinowska E, Woźniak A. Activity of superoxide dismutase and catalase and the level of lipid peroxidation products reactive with TBA in patients with psoriasis. Med Sci Monit. 2002;8(8):BR338-BR343.
25. Pastore S, Mariani V, Gubineli E, et al. Glutathione peroxidase activity in the blood cells of psoriatic patients correlates with their responsiveness to efalizumab. Free Radic Res. 2011;45(5):585-599.
26. Kidd P. Glutathione: systemic protectant against oxidative and free radical damage. Alt Med Review. 1997;2:155-176.
27. Lang CA, Naryshkin S, Schneider DL, et al. Low blood GSH in healthy aging adults. J Lab Clin Med. 1992;120:720-725.
28. Nutall SL, Martin U, Sinclair AJ, Kendall MJ. Glutathione in sickness and health. Lancet. 1998;351:645-646.
29. Anderson M. Glutathione and glutathione delivery compounds. Adv Pharmacol. 2007;38:65-78.
30. Meister A. Glutathione metabolism and itsSelective modification. J Biol Chem. 1988;263:17205-17208.
31. Lomaestro B, Malone M. Glutathione in health and disease: Pharmacotherapeutic issues. Ann Pharmacother. 1995;29:1263-1273.
32. Chan TS, O'Brian PJ. Nutritional antioxidants. In: Pantopoulos K, Schipper HM. Principles of Free Radical Biomedicine, Vol II. 1st ed. New York; Nova Science Pub; 2012: 61-77.
33. Dickenson DA, Iles KE. Glutathione. In: Pantopoulos K, Schipper HM. Principles of Free Radical Biomedicine, Vol II. 1st ed. New York; Nova Science Pub; 2012:3-19.